lobbying_activities: 831870

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
831870	9a85cbf6-6738-45e5-9e11-452a51fbe7bd	Q3	AMYLIN PHARMACEUTICALS	308536	AMYLIN PHARMACEUTICALS	2009	third_quarter	PHA	Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act Data eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726) Physician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009 FDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications Drug importation issues	Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE		330000	0	0	2009-10-16T12:45:25-04:00